Sinopharm Group Co. Ltd.
SHTDY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $584,507,930 | $596,569,565 | $552,147,550 | $521,051,235 |
| % Growth | -2% | 8% | 6% | – |
| Cost of Goods Sold | $540,252,540 | $548,057,887 | $504,713,490 | $477,000,627 |
| Gross Profit | $44,255,390 | $48,511,678 | $47,434,060 | $44,050,608 |
| % Margin | 7.6% | 8.1% | 8.6% | 8.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $8,413,544 | $8,678,071 | $8,183,559 | $7,760,993 |
| SG&A Expenses | $25,572,183 | $26,149,763 | $24,903,120 | $23,198,526 |
| Sales & Mktg Exp. | $17,158,639 | $17,471,692 | $16,719,561 | $15,437,533 |
| Other Operating Expenses | $2,494,804 | $2,152,720 | $1,926,474 | $1,140,106 |
| Operating Expenses | $28,066,987 | $28,302,483 | $26,829,594 | $24,338,632 |
| Operating Income | $16,188,403 | $20,209,195 | $20,604,466 | $19,711,976 |
| % Margin | 2.8% | 3.4% | 3.7% | 3.8% |
| Other Income/Exp. Net | -$2,187,504 | -$697,058 | -$2,040,647 | -$2,708,814 |
| Pre-Tax Income | $14,000,899 | $19,512,137 | $18,563,819 | $17,003,162 |
| Tax Expense | $3,577,305 | $4,502,309 | $4,218,377 | $3,938,389 |
| Net Income | $7,049,683 | $9,053,760 | $8,525,655 | $7,758,646 |
| % Margin | 1.2% | 1.5% | 1.5% | 1.5% |
| EPS | 11.3 | 14.5 | 13.65 | 12.45 |
| % Growth | -22.1% | 6.2% | 9.6% | – |
| EPS Diluted | 11.3 | 14.5 | 13.65 | 12.45 |
| Weighted Avg Shares Out | 624,106 | 624,131 | 624,131 | 622,234 |
| Weighted Avg Shares Out Dil | 624,106 | 624,131 | 624,131 | 622,234 |
| Supplemental Information | – | – | – | – |
| Interest Income | $616,970 | $526,213 | $542,767 | $558,562 |
| Interest Expense | $2,734,038 | $2,956,587 | $3,520,326 | $3,756,835 |
| Depreciation & Amortization | $2,355,878 | $4,430,248 | $4,165,019 | $3,922,058 |
| EBITDA | $20,174,941 | $26,898,972 | $26,249,164 | $24,682,055 |
| % Margin | 3.5% | 4.5% | 4.8% | 4.7% |